Stéphane Postic

Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA.

Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific.

Biolog-id SAS develops radio frequency identification electronic tags. It is a designer-integrator specializing in the development of traceability solutions for health products, such as labile blood products (packed red blood cells, platelets, therapeutic plasma), plasma for fractionation and cancer chemotherapy. The company was founded in 1981 and is headquartered in Paris, France.

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore.

Fondation Fondamental is a research organization that focuses on mental illnesses. The private company is based in Creteil, France. The French company's mission is to advance research in this field and help reduce the impact of mental illnesses.

Part of Pfizer Inc., Jouveinal is a French company that manufactures and markets pharmaceuticals, consumer health care products, and confectionery. The company is located in France. Jouveinal was acquired by Warner-Lambert Co. on May 21, 1997.

LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France.

Part of Rubis SCA, SA de la Raffinerie des Antilles is a French company that owns and operates an oil refinery. The company is based in Le Lamentin, France. The company was founded in 1969. Philippe Guy has been the CEO of the company since 2016.

Mirion Technologies (US), Inc. engages in the provision of nuclear measurement and detection systems. It offers measurement and enterprise, calibration, customer training programs, installation, product support and repairs, consulting, and instadose dosimetry services. The company was founded in December 2005 and is headquartered in San Ramon, CA.

Part of Thales SA, Gemplus is a digital identity and French security company that provides identity management and data protection technologies to businesses and governments. The company's solutions help facilitate secure digital interactions, such as fund exchanges for banks, cross-border travel for individuals, and smarter energy management. All relevant product and service information can be found on their website under the Thales Digital Identity & Security section.

Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Clexio Biosciences Ltd. develops novel therapies for patients suffering from neurological and psychiatric conditions. The private company is based in Jerusalem, Israel. The Israeli company was founded by Elena Kagan, Elisabeth Kogan, Menashe Levy. Elisabeth Kogan has been the CEO since incorporation.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY.

Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France.

Matignon Technologies II FCPR invests in early to later-stage companies mostly located in France and the European Union. It focuses on companies in the medical field or in the information technology sectors with revenues below €50 million. It invests between €500,000 and €10 million from early stage to growth operations.